OT
Ophthalmic Therapeutic Innovation develops disease‑modifying drugs for glaucoma, focusing on intra‑ocular pressure normalization and ocular tissue rejuvenation. Its lead candidate, OTI‑2024, is a first‑in‑class adenosine‑based MMP agent designed to address the root causes of glaucoma progression. The company advances its pipeline through clinical trials and partners with pharmaceutical firms for licensing and commercialization.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Ophthalmic Therapeutic Innovation develops ophthalmic drugs targeting intraocular pressure normalization and tissue rejuvenation for glaucoma patients. Their lead candidate, OTI‑2024, is an adenosine‑based MMP inhibitor designed to address the root causes of disease progression. The company focuses on delivering first‑in‑class therapies that improve long‑term visual outcomes.